Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Chemotherapy of advanced ovarian cancer.
Martoni A, Cacciari N, Angelelli B, Zamagni C, Pannuti F. Martoni A, et al. Among authors: zamagni c. Front Biosci. 1997 Mar 15;2:g20-6. Front Biosci. 1997. PMID: 9159262
Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.
Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group. Bengala C, et al. Among authors: zamagni c. Br J Cancer. 2006 Apr 10;94(7):1016-20. doi: 10.1038/sj.bjc.6603060. Br J Cancer. 2006. PMID: 16570045 Free PMC article.
BRCA-associated ovarian cancer: from molecular genetics to risk management.
Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D. Girolimetti G, et al. Among authors: zamagni c. Biomed Res Int. 2014;2014:787143. doi: 10.1155/2014/787143. Epub 2014 Jul 22. Biomed Res Int. 2014. PMID: 25136623 Free PMC article. Review.
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer: ROSiA Single-Arm Phase 3B Study.
Oza AM, Selle F, Davidenko I, Korach J, Mendiola C, Pautier P, Chmielowska E, Bamias A, DeCensi A, Zvirbule Z, González-Martín A, Hegg R, Joly F, Zamagni C, Gadducci A, Martin N, Robb S, Colombo N. Oza AM, et al. Among authors: zamagni c. Int J Gynecol Cancer. 2017 Jan;27(1):50-58. doi: 10.1097/IGC.0000000000000836. Int J Gynecol Cancer. 2017. PMID: 27749456 Free PMC article. Clinical Trial.
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡.
Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Conte P, et al. Among authors: zamagni c. Ann Oncol. 2018 Dec 1;29(12):2328-2333. doi: 10.1093/annonc/mdy414. Ann Oncol. 2018. PMID: 30219886 Free article. Clinical Trial.
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF. Dieci MV, et al. Among authors: zamagni c. BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z. BMC Med. 2019. PMID: 31747948 Free PMC article. Clinical Trial.
161 results